[go: up one dir, main page]

MX2017013886A - Azabenzimidazoles y su uso como moduladores del receptor ampa. - Google Patents

Azabenzimidazoles y su uso como moduladores del receptor ampa.

Info

Publication number
MX2017013886A
MX2017013886A MX2017013886A MX2017013886A MX2017013886A MX 2017013886 A MX2017013886 A MX 2017013886A MX 2017013886 A MX2017013886 A MX 2017013886A MX 2017013886 A MX2017013886 A MX 2017013886A MX 2017013886 A MX2017013886 A MX 2017013886A
Authority
MX
Mexico
Prior art keywords
azabenzimidazoles
receptor modulators
ampa receptor
formula
compounds
Prior art date
Application number
MX2017013886A
Other languages
English (en)
Other versions
MX376113B (es
Inventor
Devin M Swanson
Chen Gang
Zhang Wei
Ravula Suchitra
M Savall Bradley
K Ameriks Michael
G B Berry Cynthia
Loic Jourdan Fabrice
Patrick Lebold Terry
Wei LIN David
Wu Dongpei
Angel Pena Piñón Miguel
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2017013886A publication Critical patent/MX2017013886A/es
Publication of MX376113B publication Critical patent/MX376113B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En la presente invención se proporcionan compuestos de la Fórmula (I) y sales farmacéuticamente aceptables, N-óxidos o solvatos de estos; (ver Fórmula) además, se proporcionan en la presente invención composiciones farmacéuticas que comprenden compuestos de la Fórmula (I) y métodos para usar los compuestos de la Fórmula (I).
MX2017013886A 2015-04-29 2016-04-28 Derivados de azabenzimidazoles como moduladores del receptor ampa, y el uso de los mismos en el tratamiento de enfermedades asociadas con los receptores ampa. MX376113B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562154313P 2015-04-29 2015-04-29
PCT/US2016/029801 WO2016176460A1 (en) 2015-04-29 2016-04-28 Azabenzimidazoles and their use as ampa receptor modulators

Publications (2)

Publication Number Publication Date
MX2017013886A true MX2017013886A (es) 2018-03-12
MX376113B MX376113B (es) 2025-03-07

Family

ID=56008859

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013886A MX376113B (es) 2015-04-29 2016-04-28 Derivados de azabenzimidazoles como moduladores del receptor ampa, y el uso de los mismos en el tratamiento de enfermedades asociadas con los receptores ampa.

Country Status (39)

Country Link
US (5) US11312712B2 (es)
EP (3) EP3288940B9 (es)
JP (2) JP6800886B2 (es)
KR (2) KR102782808B1 (es)
CN (1) CN107835814B (es)
AR (1) AR104447A1 (es)
AU (2) AU2016255434C1 (es)
BR (2) BR122023023802A2 (es)
CA (1) CA2983826A1 (es)
CO (1) CO2017011017A2 (es)
CR (1) CR20170484A (es)
CY (1) CY1124059T1 (es)
DK (1) DK3288940T5 (es)
EA (1) EA033281B1 (es)
EC (1) ECSP17074645A (es)
ES (1) ES2865330T3 (es)
GT (1) GT201700231A (es)
HR (1) HRP20210403T1 (es)
HU (1) HUE053943T2 (es)
IL (1) IL254848B (es)
JO (1) JO3654B1 (es)
LT (1) LT3288940T (es)
MA (1) MA41988B1 (es)
MD (1) MD3288940T2 (es)
MX (1) MX376113B (es)
MY (1) MY194104A (es)
NI (1) NI201700129A (es)
PH (1) PH12017501816B1 (es)
PL (1) PL3288940T3 (es)
PT (1) PT3288940T (es)
RS (1) RS61688B1 (es)
SG (1) SG11201708190UA (es)
SI (1) SI3288940T1 (es)
SM (1) SMT202100222T1 (es)
TW (1) TWI706952B (es)
UA (1) UA120304C2 (es)
UY (1) UY36654A (es)
WO (1) WO2016176460A1 (es)
ZA (1) ZA201708065B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY36654A (es) 2015-04-29 2016-10-31 Janssen Pharmaceutica Nv Azabenzimidazoles con propiedades moduladoras del receptor ampa y composiciones farmacéuticas que los contienen
ES2759348T3 (es) * 2015-04-29 2020-05-08 Janssen Pharmaceutica Nv Imidazopirazinas y pirazolopirimidinas y su utilización como moduladores de receptores AMPA
CN118853581A (zh) 2017-06-21 2024-10-29 美商生物细胞基因治疗有限公司 嵌合抗原受体(CARs)、组合物及其使用方法
CN107383004B (zh) * 2017-07-05 2020-04-17 浙江大学 2-氨基咪唑并吡啶类衍生物及制备和应用
EP3679027A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Dihydrobenzimidazolones
ES2971497T3 (es) 2017-10-06 2024-06-05 Takeda Pharmaceuticals Co Compuestos heterocíclicos
SI3860998T1 (sl) 2018-10-05 2024-06-28 Annapurna Bio Inc. Spojine in sestavki za zdravljenje stanj, povezanih z aktivnostjo apj-receptorja
KR20210097124A (ko) 2018-10-30 2021-08-06 리페어 세라퓨틱스 인크. 화합물, 약제 조성물, 및 화합물 제조 방법 및 atr 키나제 억제제로서의 이것들의 사용 방법
KR102907028B1 (ko) 2019-02-13 2026-01-05 피티씨 테라퓨틱스, 인크. 가족성 자율신경실조증 치료를 위한 티오에노[3,2-b]피리딘-7-아민 화합물
US12398140B2 (en) 2019-02-13 2025-08-26 Ptc Therapeutics, Inc. Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomia
WO2020181232A1 (en) 2019-03-06 2020-09-10 C4 Therapeutics, Inc. Heterocyclic compounds for medical treatment
AU2020317381A1 (en) * 2019-07-22 2022-02-10 Repare Therapeutics Inc. Substituted 2-morpholinopyridine derivatives as ATR kinase inhibitors
WO2022133046A2 (en) * 2020-12-16 2022-06-23 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN114591338B (zh) * 2022-03-31 2023-05-09 苏州欧康维视生物科技有限公司 一种Syk和VEGFR2双靶点抑制剂的制备方法及其用途
CN115304599A (zh) * 2022-09-20 2022-11-08 浙大宁波理工学院 一种3-溴-6-异丙基-1氢-哌咯[2，3-b]并吡啶及其制备方法
CN117402148A (zh) * 2023-07-26 2024-01-16 青岛大学 一种氮-氮苯并咪唑轴手性化合物及其制备方法和应用
WO2025155167A1 (ko) * 2024-01-17 2025-07-24 주식회사 엘지화학 Cbp/p300 저해제로 사용되는 신규 화합물, 및 이를 유효성분으로 포함하는 암, 염증성 장애 또는 자가면역 질환의 예방 또는 치료용 약학 조성물
WO2025155830A1 (en) 2024-01-17 2025-07-24 Rapport Therapeutics, Inc. Crystalline forms of 3-(7-chloro-1h-indazol-5-yl)-2,5-bis(trifluoromethyl)-3h-imidazo[4,5-b]pyridine and their use in the treatment of epilepsy
WO2025217330A1 (en) * 2024-04-10 2025-10-16 Terremoto Biosciences, Inc. Cysteine covalent modifiers of akt1 and uses thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55167282A (en) 1979-06-12 1980-12-26 Fujisawa Pharmaceut Co Ltd Piperazine derivative or its salt and its preparation
CN1051313A (zh) 1990-11-07 1991-05-15 鞍山市振东工业尼龙厂 尼龙球磨罐及其热装工艺
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
TW251284B (es) 1992-11-02 1995-07-11 Pfizer
CN1067386C (zh) 1994-02-10 2001-06-20 辉瑞大药厂 作为苯并二氮杂䓬受体位的兴奋剂和拮抗药的5－杂芳基吲哚衍生物
US5565483A (en) 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
UA54403C2 (uk) 1996-10-01 2003-03-17 Н'Юросерч А/С Похідні індол-2,3-діон-3-оксиму, фармацевтична композиція, спосіб лікування розладу чи захворювання ссавців, у тому числі людини та спосіб одержання похідних індол-2,3-діон-3-оксиму
AU2931099A (en) 1998-03-06 1999-09-20 Janssen Pharmaceutica N.V. Crf antagonistic pyrazolo(4,3-b)pyridines
DE19812331A1 (de) 1998-03-20 1999-09-23 Merck Patent Gmbh Piperidinderivate
JP2002519373A (ja) * 1998-07-02 2002-07-02 エーザイ株式会社 製薬組成物及びそれらの使用
CN1356872A (zh) 1998-12-31 2002-07-03 苏根公司 调节蛋白激酶活性和用于癌症化疗的3－亚杂芳基－2－吲哚满酮化合物
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
AU2001282865A1 (en) 2000-08-11 2002-02-25 Eli Lilly And Company Heterocyclic sulfonamide derivatives
US6548576B1 (en) 2001-11-07 2003-04-15 Bourns, Inc. Epoxy formulation adapted to be used in conjunction with no-lead solder in electronic components
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
JP5209311B2 (ja) * 2004-09-03 2013-06-12 メルク セローノ ソシエテ アノニム ピリジンメチレンアゾリジノン及びホスホイノシチド阻害剤としてのその使用
US8283364B2 (en) 2005-09-30 2012-10-09 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
WO2007135529A2 (en) 2006-05-23 2007-11-29 Pfizer Products Inc. Azabenzimidazolyl compounds as mglur2 potentiators
DE602007013450D1 (de) 2006-11-03 2011-05-05 Glaxo Group Ltd Verbindungen, die den ampa-rezeptor verstärken, und deren anwendung in der medizin
WO2008113795A1 (en) 2007-03-20 2008-09-25 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
GB0711089D0 (en) 2007-06-08 2007-07-18 Glaxo Group Ltd Compounds
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
WO2009067607A2 (en) 2007-11-20 2009-05-28 Memory Pharmaceuticals Corporation Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders
WO2009073777A1 (en) 2007-12-06 2009-06-11 Schering Corporation Gamma secretase modulators
TW201012803A (en) 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
WO2010005528A2 (en) * 2008-06-30 2010-01-14 Ironwood Pharmaceuticals Incorporated Pyrrolopyridine carboxylic acid derivatives
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
GB0822425D0 (en) 2008-12-09 2009-01-14 Glaxo Group Ltd Compounds
GB0822981D0 (en) 2008-12-17 2009-01-21 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
WO2011056985A2 (en) 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
EA201290774A1 (ru) 2010-02-11 2013-03-29 Вандербилт Юниверсити Пиразолопиридиновые, пиразолопиразиновые, пиразолопиримидиновые, пиразолотиофеновые и пиразолотиазоловые соединения как аллостерические потенциаторы mglur4, композиции и способы лечения неврологических дисфункций
WO2011156245A2 (en) * 2010-06-09 2011-12-15 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
NZ605889A (en) 2010-06-24 2014-10-31 Takeda Pharmaceutical Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors
KR101852215B1 (ko) 2010-08-10 2018-04-25 다케다 야쿠힌 고교 가부시키가이샤 헤테로시클릭 화합물 및 이의 용도
WO2012021382A1 (en) 2010-08-12 2012-02-16 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
MX2014005304A (es) 2011-10-31 2015-03-20 Xenon Pharmaceuticals Inc Biaril eter sulfonamidas y su uso como agentes terapeuticos.
WO2013130501A1 (en) 2012-03-01 2013-09-06 The Board Of Regents Of The University Of Texas System Bivalent ampa receptor positive allosteric modulators
GB201205669D0 (en) * 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
JO3225B1 (ar) * 2012-11-27 2018-03-08 Lilly Co Eli 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8
SG11201505878UA (en) 2013-02-19 2015-09-29 Pfizer Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders
TW201609719A (zh) 2014-05-28 2016-03-16 美國禮來大藥廠 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物
MA51438A (fr) 2015-04-03 2021-04-14 Incyte Corp Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
UY36654A (es) 2015-04-29 2016-10-31 Janssen Pharmaceutica Nv Azabenzimidazoles con propiedades moduladoras del receptor ampa y composiciones farmacéuticas que los contienen
WO2018080918A1 (en) 2016-10-26 2018-05-03 Janssen Pharmaceutica Nv 3-aryl-2h-pyrazolo[4,3-b]pyridine compounds and their use as ampa receptor modulators
CN109890823B (zh) 2016-10-26 2021-11-30 詹森药业有限公司 稠合氮杂环化合物及其作为ampa受体调节剂的用途
CA3039676A1 (en) 2016-10-26 2018-05-03 Janssen Pharmaceutica Nv Fused bicylic pyridine compounds and their use as ampa receptor modulators
CA3094609A1 (en) 2018-04-09 2019-10-17 Raqualia Pharma Inc. Fused cyclic urea derivatives as crhr2 antagonist
US12479845B2 (en) 2019-02-01 2025-11-25 Hanmi Pharm. Co., Ltd. Imidazopyridine derivative compounds and use of same

Also Published As

Publication number Publication date
JP2021042230A (ja) 2021-03-18
IL254848A0 (en) 2017-12-31
JP6800886B2 (ja) 2020-12-16
PL3288940T3 (pl) 2021-07-12
DK3288940T3 (da) 2021-05-25
US20230110576A1 (en) 2023-04-13
US12139485B2 (en) 2024-11-12
EP3288940A1 (en) 2018-03-07
MA41988B1 (fr) 2021-03-31
NI201700129A (es) 2019-05-10
MA41988A (fr) 2018-07-03
CN107835814A (zh) 2018-03-23
SMT202100222T1 (it) 2021-05-07
BR122023023802A2 (pt) 2023-12-26
EA033281B1 (ru) 2019-09-30
EP4144736A1 (en) 2023-03-08
BR112017023147B1 (pt) 2024-04-30
NZ774642A (en) 2024-09-27
NZ736057A (en) 2023-08-25
RS61688B1 (sr) 2021-05-31
CY1124059T1 (el) 2022-05-27
GT201700231A (es) 2018-12-20
HK1252249A1 (en) 2019-05-24
ZA201708065B (en) 2019-09-25
TW201708217A (zh) 2017-03-01
JO3654B1 (ar) 2020-08-27
UY36654A (es) 2016-10-31
HRP20210403T1 (hr) 2021-10-29
CA2983826A1 (en) 2016-11-03
CR20170484A (es) 2018-02-26
JP7026194B2 (ja) 2022-02-25
SI3288940T1 (sl) 2021-07-30
EP3901153A1 (en) 2021-10-27
HUE053943T2 (hu) 2021-08-30
US20180118740A1 (en) 2018-05-03
EA201792374A1 (ru) 2018-05-31
KR102782808B1 (ko) 2025-03-14
AU2020210231A1 (en) 2020-08-20
AU2020210231B2 (en) 2021-07-22
IL254848B (en) 2021-01-31
PH12017501816B1 (en) 2023-07-19
WO2016176460A1 (en) 2016-11-03
LT3288940T (lt) 2021-05-10
ES2865330T3 (es) 2021-10-15
MY194104A (en) 2022-11-11
AU2016255434B2 (en) 2020-05-14
PH12017501816A1 (en) 2018-04-23
US11312712B2 (en) 2022-04-26
AR104447A1 (es) 2017-07-19
TWI706952B (zh) 2020-10-11
US20210284641A1 (en) 2021-09-16
CN107835814B (zh) 2021-07-23
CO2017011017A2 (es) 2018-03-20
DK3288940T5 (da) 2021-09-20
SG11201708190UA (en) 2017-11-29
US20250230157A1 (en) 2025-07-17
ECSP17074645A (es) 2018-02-28
JP2018518462A (ja) 2018-07-12
KR20240017991A (ko) 2024-02-08
EP3288940B1 (en) 2021-02-24
UA120304C2 (uk) 2019-11-11
US20230114165A1 (en) 2023-04-13
MX376113B (es) 2025-03-07
PT3288940T (pt) 2021-04-30
US12304908B2 (en) 2025-05-20
AU2016255434A1 (en) 2017-10-26
BR112017023147A2 (pt) 2018-07-10
AU2016255434C1 (en) 2021-09-23
KR20170140382A (ko) 2017-12-20
EP3288940B9 (en) 2021-07-21
US12145934B2 (en) 2024-11-19
MD3288940T2 (ro) 2021-08-31

Similar Documents

Publication Publication Date Title
MX2017013886A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa.
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
MX2018003432A (es) Compuestos heterociclicos y usos de los mismos.
DOP2017000151A (es) Derivados de quinazolina utilizados para tratar el vih
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
DOP2015000158A (es) Inhibidores de prmt5 y sus usos
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
UY35485A (es) Compuestos heterocíclicos y usos de los mismos
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
ECSP17069696A (es) Compuestos novedosos
ECSP16074478A (es) Compuestos novedosos
CO2019004164A2 (es) Compuestos de piridina bicíclicos fusionados y su uso como moduladores de receptores ampa
MX2017000183A (es) Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides.
MX2017013877A (es) Compuestos de benzimidazolona y benzotiazolona y su uso como moduladores del receptor ampa.
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
CO2019004143A2 (es) Compuestos azaheterocíclicos fusionados y su uso como moduladores de los receptores ampa
CR20160373A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina
EA201891680A1 (ru) Производные индана в качестве модуляторов mglur7
MX369806B (es) Compuestos de indolona y su uso como moduladores del receptor ampa.
CR20190028A (es) Compuestos heterocíclicos como inmunomoduladores
UY36464A (es) Compuestos de quinazolina

Legal Events

Date Code Title Description
FG Grant or registration